Workflow
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
CRDLCardiol Therapeutics(CRDL) Newsfile·2024-11-18 16:37
          Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024November 18, 2024 11:37 AM EST | Source: Cardiol Therapeutics Inc.Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 ...